AngioDynamics, Inc. (ANGO) News
Follow AngioDynamics, Inc. (ANGO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Humana Medicare Advantage policy covers AngioDynamics NanoKnife IRE
AngioDynamics says Humana’s Medicare Advantage coverage policy supports broader access to NanoKnife IRE for prostate and liver cancer.
EQUITY | Oct 14, 2026, 11:03 AM UTC
H
AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics Inc. (NASDAQ: ANGO ) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results. Trading activity was elevated, with approximately 1.94 million shares changi
LIVE | Oct 08, 2026, 05:44 PM UTC
H
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.39% to 50,978.59 while the NASDAQ declined 0.61% to 27,371.84. The S&P 500 also fell,
LIVE | Oct 08, 2026, 04:03 PM UTC
H
AngioDynamics Q1 2027 Earnings Call: Complete Transcript
AngioDynamics (NASDAQ: ANGO ) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-
LIVE | Oct 08, 2026, 01:11 PM UTC
H
AngioDynamics Affirms FY2027 Adj EPS Guidance of $(0.29)-$(0.24) vs $(0.27) Est; Affirms FY2027 Sales Guidance of $336.000M-$341.000M vs $337.400M Est
AngioDynamics (NASDAQ: ANGO ) affirms FY2027 Adj EPS guidance from $(0.29)-$(0.24) to $(0.29)-$(0.24) vs $(0.27) analyst estimate. Affirms FY2027 sales outlook from $336.000 million-$341.000 million to $336.000 million-$
LIVE | Oct 08, 2026, 10:03 AM UTC
M
AngioDynamics reports Q1 sales of $80.9M, appoints new CEO
AngioDynamics posted Q1 FY27 net sales of $80.9M (+6.9% YoY), with gross margin of 59.4% and an adjusted net loss of $1.8M. The company reiterated FY27 guidance and said Eric Honroth will become CEO effective Nov. 2, 202
EQUITY | Oct 08, 2026, 10:02 AM UTC
M
AngioDynamics reports FY2027 first-quarter financial results
EQUITY | Oct 08, 2026, 10:02 AM UTC
M
AngioDynamics reports 1Q loss of $7.1 million
EARNINGS | Oct 08, 2026, 10:02 AM UTC
M
ANGO Q1'26 EPS estimate is (0.11) USD
AngioDynamics, Inc. (ANGO) is scheduled to report its Q1'26 financial results before market open on October 08. The company's revenue is projected at 80.51 million USD, with an anticipated Earnings Per Share (EPS) of (0.
EQUITY | Oct 07, 2026, 11:00 AM UTC
L
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today annou
EARNINGS | Sep 28, 2026, 08:30 PM UTC
H
AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Previous quarterly performance (using preferred earnings measure in US dollars). This summary was machine generated September 28 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning
EARNINGS | Sep 28, 2026, 12:32 PM UTC
H
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company Symbol Quarter Mean Report Time ·Monday ·Sangoma Tech (SANG)
EARNINGS | Sep 28, 2026, 10:00 AM UTC
H
ANGO Q1'26 Earnings: revenue estimate is 80.51M USD
ANGO (AngioDynamics, Inc.) is set to announce its Q1'26 results on October 01, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 80.51 million USD w
EARNINGS | Sep 24, 2026, 11:00 AM UTC
L
ANGO Raise PT to $20 from $16 as NanoKnife powers a strong FQ4 beat and initial FY27 guide above expectations @ Canaccord
ANGO Raise PT to $20 from $16 as NanoKnife powers a strong FQ4 beat and initial FY27 guide above expectations @ Canaccord
EQUITY | Jul 15, 2026, 01:04 PM UTC
H
Earnings Calendar: • Earnings Before the Open: ANGO BAC C CRMT Eric FAST GS JPM WFC • Earnings After the Close: AEHR EQBK KMTS PXED
Earnings Calendar: • Earnings Before the Open: ANGO BAC C CRMT Eric FAST GS JPM WFC • Earnings After the Close: AEHR EQBK KMTS PXED
EARNINGS | Jul 14, 2026, 11:01 AM UTC
L
ANGO Q4 sales $86.6M tops ests $80.4M; Q4 EPS loss (-$0.07) vs. est. loss (-$0.09); guides Fy27 sales outlook $336-$341M as expects Med Tech
ANGO Q4 sales $86.6M tops ests $80.4M; Q4 EPS loss (-$0.07) vs. est. loss (-$0.09); guides Fy27 sales outlook $336-$341M as expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat; sees gross ma
EARNINGS | Jul 14, 2026, 10:26 AM UTC
H
ANGO Angiodynamics RESULTS: Q4, Q4 sales $86.6M, Q4 ADJ Net Income $-2.8M, Q4 ADJ EPS $-0.07, Q4 Net Income $-11.4M, Angiodynamics Earnings
ANGO Angiodynamics RESULTS: Q4, Q4 sales $86.6M, Q4 ADJ Net Income $-2.8M, Q4 ADJ EPS $-0.07, Q4 Net Income $-11.4M, Angiodynamics Earnings Notes:, Outlook FY ADJ EPS $-0.29 to -0.24, Outlook FY sales $336-341M, For fisc
RATES | Jul 14, 2026, 10:24 AM UTC